| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg | |||
| Other Sizes |
| Targets |
Not applicable. Glycidyl stearate-d5 is not a pharmacologically active drug; it is a stable isotope-labeled internal standard used in analytical chemistry. Its "target" is the analytical measurement process, where it serves as a tracer for quantifying glycidyl stearate by correcting for matrix effects, extraction recovery, and ionization efficiency variations in mass spectrometry. It is not designed to interact with any biological receptor or enzyme.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as tracers that influence measurement during the drug development process. It's possible that the pharmacokinetics and functional range of medications contribute to the concern over mutagenesis [1].
Not applicable (no biological activity). The "in vitro activity" of Glycidyl stearate-d5 is defined analytically rather than pharmacologically. Its key property is providing identical chromatographic retention time and ionization behavior as the unlabeled glycidyl stearate while being distinguishable by a +5 Da mass shift. This allows it to serve as an ideal internal standard, achieving 1-3 microg/kg method detection limits and 84-108% recoveries in spiked food samples. |
| ln Vivo |
Not applicable (no in vivo biological activity). Glycidyl stearate-d5 is not intended for in vivo pharmacological studies. As a stable isotope-labeled compound, its use is limited to analytical chemistry applications. It does not exert any therapeutic effects, nor is it administered to living organisms for the purpose of studying drug efficacy.
|
| Enzyme Assay |
Not applicable. Glycidyl stearate-d5 is used as an internal standard in analytical chemistry rather than in enzyme or receptor binding assays. A typical non-cellular analytical workflow involves: preparation of calibration standards and quality control samples spiked with the d5-labeled standard; extraction of samples using organic solvents; separation by reversed-phase HPLC; and detection by tandem mass spectrometry (LC-MS/MS) operated in multiple reaction monitoring mode. The d5-labeled compound co-elutes with the native analyte but is detected at a different mass transition.
|
| Cell Assay |
Not applicable. Glycidyl stearate-d5 is not used in cell-based assays, as it lacks biological activity and is intended solely as an analytical standard. It is not tested on cell lines for pharmacological effects, cytotoxicity, or target modulation. Its use is confined to in vitro analytical chemistry procedures involving the preparation and processing of food or biological samples for quantification of glycidyl ester contaminants.
|
| Animal Protocol |
Not applicable. Glycidyl stearate-d5 is not used in animal experiments or in vivo studies. It is strictly a research-grade analytical standard for chemical testing. No protocols exist for administering this compound to animals to study pharmacokinetics, efficacy, or safety, as it has no drug-like properties or therapeutic potential. Its applications are limited to laboratory-based quantification of glycidyl esters in food safety and exposure monitoring.
|
| ADME/Pharmacokinetics |
Not applicable. Glycidyl stearate-d5 is not a drug candidate; therefore, no pharmacokinetic parameters (such as absorption, distribution, metabolism, or excretion) are relevant or reported. The compound is used ex vivo as an analytical standard. It is supplied as a neat solid or in solution, stable for up to 3 years at -20degC as a powder and for 6 months at -80degC in solvent.
|
| Toxicity/Toxicokinetics |
Not applicable. Toxicity studies are not conducted for analytical reference standards like Glycidyl stearate-d5. The compound is not intended for human consumption or therapeutic use. However, as a chemical reagent, it should be handled with appropriate laboratory safety precautions, including the use of personal protective equipment, to avoid inhalation, ingestion, or skin contact.
|
| References |
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-246.
|
| Additional Infomation |
Glycidyl stearate-d5 is exclusively a stable isotope-labeled internal standard for quantitative mass spectrometry. It is not a drug, has no clinical trial history, and is not approved for any therapeutic indication. Its development supports regulatory compliance for food safety testing (e.g., ISO/IEC 17025, FDA/EFSA standards). The unlabeled compound (glycidyl stearate) is an industrial chemical used as a low-calorie fat mimetic and in coatings and surfactants.
|
| Molecular Formula |
C21H35D5O3
|
|---|---|
| Molecular Weight |
345.57
|
| Exact Mass |
345.329
|
| CAS # |
1346598-19-3
|
| Related CAS # |
Glycidyl stearate;7460-84-6
|
| PubChem CID |
71317147
|
| Appearance |
White to off-white solid powder
|
| Density |
0.9±0.1 g/cm3
|
| Boiling Point |
424.7±18.0 °C at 760 mmHg
|
| Melting Point |
52-54° C
|
| Flash Point |
161.8±6.1 °C
|
| Vapour Pressure |
0.0±1.0 mmHg at 25°C
|
| Index of Refraction |
1.462
|
| LogP |
8.73
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
19
|
| Heavy Atom Count |
24
|
| Complexity |
291
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCCCCCCCCCCCCCC(OC(C1(OC1([2H])[2H])[2H])([2H])[2H])=O
|
| InChi Key |
OUQGOXCIUOCDNN-UITAJUKKSA-N
|
| InChi Code |
InChI=1S/C21H40O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-21(22)24-19-20-18-23-20/h20H,2-19H2,1H3/i18D2,19D2,20D
|
| Chemical Name |
[dideuterio-(2,3,3-trideuteriooxiran-2-yl)methyl] octadecanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8938 mL | 14.4688 mL | 28.9377 mL | |
| 5 mM | 0.5788 mL | 2.8938 mL | 5.7875 mL | |
| 10 mM | 0.2894 mL | 1.4469 mL | 2.8938 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
